Orna Therapeutics Presents New Preclinical Data Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases at the American Society of Gene and Cell Therapy Annual Meeting
Excerpt from the Press Release:
WATERTOWN, Mass., May 15, 2025 /PRNewswire/ — Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during an oral session at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana.
“The preclinical data presented today at ASGCT highlight our potential to deliver on the promise of in vivo CAR T therapy,” said Joseph Bolen, Ph.D., Chief Executive Officer of Orna Therapeutics. “Our CD19 panCAR program has demonstrated not only successful delivery of our lead panCAR LNP to disease-relevant immune cell types, but also robust and sustained B cell depletion at low doses in both peripheral blood and lymphoid tissues in non-human primates (NHPs). These compelling results continue to reinforce our commitment to translating our promising science into meaningful therapies for patients and we look forward to advancing our CD19 panCAR program towards the clinic in 2026.”
Presentation Details:
Title: In Vivo panCAR™ Therapy Using Circular RNA for the Treatment of Autoimmune Disease
Speaker: Megan Hoban, Ph.D., panCAR Program Lead, Orna Therapeutics
Date/Time: Thursday, May 15, 2025, 8:00 AM – 9:45 AM CDT
Session Name: Cellular and Gene Therapies for Autoimmune Disease
Location: Room 388-390
In today’s presentation, Orna will showcase preclinical data demonstrating the potential of its in vivo panCAR therapy, enabled by its proprietary circular (oRNA®) technology and best-in-class lipid nanoparticle (LNP) delivery system to achieve robust and sustained B cell depletion in both humanized mouse models and non-human primates across multiple doses.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?